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Metabolic encephalopathya b s t r a c t
Beta-ketothiolase (mitochondrial acetoacetyl-CoA thiolase, T2) deficiency is an autosomal recessive dis-
order characterized by impaired metabolism of ketones and isoleucine. In this study, we report on the
first two siblings with T2 deficiency from Libya. Both siblings presented with ketoacidosis, but the sever-
ity and outcomes were quite distinctive. T2 deficiency in patient 1, the younger sister, manifested as
recurrent severe episodes of ketoacidosis during the first year of life. She unfortunately experienced neu-
rodevelopmental complications, and died at 14 months old, after her 5th episode. In contrast, patient 2,
the elder brother, experienced only one ketoacidotic episode at the age of 4 years. He recovered unevent-
fully and has continued to achieve age-appropriate development to date. Upon analysis, the siblings’
blood acylcarnitine profiles had shown increased levels of C5:1 and C5-OH carnitine. ACAT1 mutational
analysis revealed patient 2 is homozygotic for a novel mutation–c.674C > A (p.Ala225Glu); this mutation
was then confirmed by familial analysis. Transient expression analysis of c.674C > A mutant T2 cDNA
revealed neither potassium ion-activated acetoacetyl-CoA thiolase activity, which represents T2 activity,
nor mutant T2 protein. Therefore, this mutation is truly pathogenic. Interestingly, the incidence of T2
deficiency may be high among the Arab population. This disease should be considered in the differential
diagnosis for unexplained ketoacidosis in children. Patients with T2 deficiency could have a favorable
outcome if diagnosed and treated early.
 2016 Ain Shams University. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Beta-ketothiolase deficiency (Online Mendelian Inheritance in
Man [OMIM] 203750, 607809), a defect in mitochondrial
acetoacetyl-CoA thiolase (T2) (EC 2.3.1.9, gene symbol ACAT1), is
an autosomal recessive disease that affects isoleucine catabolismand ketone body utilization [1,2]. Since Daum et al. first character-
ized T2 deficiency in 1971, more than 100 patients have been diag-
nosed with the disease worldwide [3]. T2 deficiency ordinarily
manifests as intermittent ketoacidotic episodes between the ages
of 6 and 18 months; patients are usually asymptomatic between
episodes. A distinctive laboratory finding is an increased urinary
excretion of isoleucine-catabolic intermediates 2-methyl-3-
hydroxybutyrate (2M3HB), 2-methylacetoacetate (2MAA), and
tiglylglycine (TIG). In addition, blood acylcarnitine analysis usually
shows elevated C5:1 and C5-OH carnitine levels [1,2]. Neverthe-
less, some T2-deficient patients demonstrated atypical clinical
and laboratory features. The severity and frequency of episodes
vary among patients; however, the outcome is commonly favor-
able, unless a ketoacidotic episode causes life-threatening or irre-
versible sequelae [1,3].
The human ACAT1 gene is located at chromosome 11q22.3-23.1.
It spans nearly 27 kb and contains 12 exons and 11 introns.
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protein consisting of 427 amino acids [4]. ACAT1 mutations are
highly diverse; more than 70 mutations have been identified to
date. Except for p.Arg208⁄ among the Vietnamese, no other com-
mon ACAT1 mutation patterns have yet been recognized [3,5].
There are few studies on T2 deficiency in the Arab population.
Several cases have been detected by tandem mass spectrometry
(MS/MS), but the diagnoses were seldom confirmed by an enzyme
assay or genetic analysis [6–18]. In this study, we report on the
first two Libyan siblings, sister and brother, with T2 deficiency.
We describe their clinical and laboratory features and characterize
a novel ACAT1mutation. We also discuss the current situation of T2
deficiency among Arab population and review main characteristics
of this disorder, which may point to diagnostic clues.2. Patients and methods
Patient 1: The female patient was the third of four children
born to first cousins parents of Arab ancestry in Libya. She was
delivered at full term following an uneventful gestation, weighing
3 kg. There was no prior remarkable family history, as her elder
brother, patient 2, was asymptomatic at that time. The patient
thrived until 20 days of age when she was admitted to a hospital
with vomiting, diarrhea, dehydration, and acidotic breathing.
Symptomatic management, including intravenous fluids, was
given; she recovered uneventfully. A hydrolyzed milk formula
was prescribed for presumed cow’s milk protein intolerance. No
additional investigation was performed for this episode.
At 7 months of age, the patient was admitted to an intensive
care unit with dehydration, acidotic breathing, and lethargy. This
was preceded by fever, vomiting, and diarrhea for 2 days. Physical
examination revealed hepatomegaly, marked hypotonia, hypore-
flexia, and abnormal pupillary response to light, showing no reac-
tion on the right and a sluggish reaction on the left. Arterial blood
gases revealed a severe metabolic acidosis: pH 6.8, HCO3 3 mmol/L,
base excess 24, and pCO2 15 mmHg. Ketonuria was detected. A
blood count demonstrated leukocytosis (31  103/ll), mild anemia
(9.6 gm/dl), and normal platelets. Other investigations showed a
blood glucose of 2.5 mmol/L, lactate 2 mmol/L, and ammonia
145 lmol/L; her electrolytes and liver and kidney function tests
revealed no significant abnormalities. Management for an assumed
central nervous system infection, such as meningitis or encephali-
tis, was implemented. After 12 days, her general condition was sta-
bilized. She was then referred to a metabolic unit, where an organic
aciduria was suspected. A subsequent acylcarnitine analysis of
dried blood spots showed increased C5:1 (0.34 lmol/L; cut-off
point 0.12) and C5-OH (2.68 lmol/L; cut-off point 0.47) levels. Pre-
cautionary measures, including avoidance of prolonged fasting,
protein restriction (1.5 g/kg/day), carnitine supplementation
(100 mg/kg/day), and early recognition of illness symptoms, were
prescribed.
Follow-up demonstrated a neurodevelopmental delay, irritabil-
ity, progressive dystonia, choreic movements, and nystagmus. At
12 months of age, a brain magnetic resonance imaging was con-
ducted. This showed cerebral atrophy and bilateral hyperintense
areas involving caudate and putamen nuclei on T2-weighed
images. An electroencephalogram showed hypsarrhythmia. Two
mild ketoacidotic episodes, precipitated by infections, recurred at
9 and 12 months of age. At 14 months of age, the patient experi-
enced her final episode, which was more severe than her 2nd epi-
sode. She succumbed to her disease at that time.
Patient 2: The male patient, the elder brother of patient 1, was
the firstborn child of his parents. There were no remarkable ante-
natal events. He was born at full term with a birth weight of 4 kg.
He was well until 4 years and 2 months of age when he was admit-ted to an intensive care unit with vomiting, acidotic breathing,
lethargy, and generalized convulsions. This was preceded by fever,
sore throat, and poor oral intake for 5 days. Arterial blood gases
showed pH 7.11, HCO3 3.4 mmol/L, base excess 20, and pCO2
4.3 mmHg. Urinary ketone body testing was positive. Other inves-
tigations revealed severe hypoglycemia (0.95 mmol/L), ammonia
144 lmol/L, and lactate 1.67 mmol/L. Patient 2 was provisionally
diagnosed with T2 deficiency because his sister (patient 1)
had already been diagnosed with this disease one month before.
Therefore, a timely blood acylcarnitine analysis was performed.
It demonstrated increased C5:1 (0.41 lmol/L) and C5-OH
(4.13 lmol/L) levels. He was treated successfully with appropriate
intravenous glucose, fluids, bicarbonate, and electrolytes. The
previously-described precautionary measures were reinforced. At
his current age of 7.5 years, he has not suffered of any further epi-
sodes. He has attained age-appropriate growth and development.
Recently, dried blood spots were obtained from the living family
members for an ACAT1 mutational analysis.
This study was approved by the Ethical Committee of the Grad-
uate School of Medicine, Gifu University, Japan. All procedures fol-
lowed were in accordance with the ethical standards of the
responsible committee on human experimentation (institutional
and national) and with the Helsinki Declaration of 1975, as revised
in 2000. Informed consents were obtained from all participants or
their parents for inclusion in the study.
2.1. Mutation analysis
Small pieces (1.2  1.2 mm) were used for direct PCR amplifica-
tion of DNA from dried blood specimens. The 12 ACAT1 exons, with
flanking intron regions, were amplified by primer pairs as
described before [19]. PCR conditions for all segments, using a
BIOTaqTM HS DNA Polymerase (Bioline Reagents Ltd, London, UK),
were 95 C for 10 min; 40 cycles of 94 C for 30 s, 55 C for 1 min,
and 72 C for 1 min; followed by 72 C for 7 min. The 12 amplified
fragments were sequenced using a BigDye Terminator v1.1 cycle
sequencing kit (Applied Biosystems, Foster City, CA, USA) and ABI
PRISM 3130XL Genetic Analyzer (Applied Biosystems) per the
manufacturer’s directions. The genomic ACAT1 sequence (GenBank
accession NG_009888.1) was used as a reference.
2.2. Transient expression analysis
A pCAGGS eukaryote expression vector was used for transient
expression analysis of T2 cDNA, as previously described [19–21].
In brief, we used a Kod-Plus-Mutagenesis Kit (Tyobo Co.,
Osaka, Japan) to construct full-length mutant cDNA p.Ala225Glu.
Wild-type and mutant constructs were transfected via Lipofec-
tamine 2000 (Invitrogen, San Diego, CA, USA) into 5  105 SV40-
transformed T2-deficient fibroblasts. After incubation at 37 C for
72 h, cells were harvested and stored at 80 C until needed. After
that, cells were freeze–thawed and sonicated in 50 mM sodium
phosphate (pH 8.0) and 0.1% Triton X-100. This was followed by
centrifugation at 10,000g for 10 min. Supernatants from cell
extracts were used for enzyme assay and immunoblot analysis.
We spectrophotometrically monitored the decrease of
acetoacetyl-CoA absorbance at 303 nm, which is caused by
acetoacetyl-CoA thiolysis to acetyl-CoA. Acetoacetyl-CoA thiolase
activity, was measured in the absence and presence of potassium
ions. Potassium ions specifically stimulate T2; hence, the difference
represents T2 activity [19,21]. We calculated the average and stan-
dard errors of three independent experiments. An immunoblot
analysis was performed as previously described [19,22]. We used
a mixture of an anti-T2 and anti-succinyl-CoA:3-oxoacid CoA
transferase (SCOT) antibodies as the first antibody. Serial dilution
samples extracted from the wild-type (10, 5, 2.5, and 1.25 lg) were
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Therefore, we could estimate the amount of any detected mutant
T2 protein compared to wild-type.3. Results
Patient 2 has a novel homozygous mutation c.674C > A (p.
Ala225Glu) in exon 7 of ACAT1 gene. This was confirmed by familial
analysis; both parents and the younger brother are heterozygotes
for the same mutation (Supplementary material 1). The expression
of wild-type T2 cDNA yielded high potassium ion-activated
acetoacetyl-CoA thiolase activity, which represents T2 activity. In
contrast, p.Ala225Glu mutation, like mock cDNA, did not produce
any detectable T2 enzyme activity (Fig. 1A). In immunoblot analy-
sis (Fig. 1B), no p.Ala225Glu mutant T2 protein was detected. The
smallest used amount of wild type (1.25 lg) was clearly visible.
Therefore, the amount of p.Ala225Glu mutant T2 protein, if any,
would be 12.5% less than that of wild-type.4. Discussion
The classically-termed ‘‘Arab world” consists of 22 Arabic-
speaking countries over approximately 13  106 km2, and has a
population of approximately 425 million. Several patients with
T2 deficiency have been identified in different Arab countries,
mostly through case reports, retrospective studies, or selective
screening (Table 1). Emerging nationwide newborn screening
(NBS) programs by MS/MS have recently been launched in only a
few Arab countries (including Qatar, Saudi Arabia, and the United
Arab Emirates) [16]. The incidence of T2 deficiency has been esti-
mated by three Arab studies to be 1.4, 1.6, and 2.76 per 100,000
newborns [11,16,18]. These numbers are higher than the reported
figures of 1 per 313,000 in North Carolina, and 1 per 232,000 new-
borns in Minnesota, USA [23,24]. As some patients may not be
detected by NBS programs using MS/MS, the true incidence of T2
deficiency is likely higher [3]. This may be expected due to the high
rate of consanguineous marriages among Arab populations [16,18].
The typical presentation of T2 deficiency consists of intermit-
tent episodes of ketoacidosis that are usually triggered by infec-
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Fig. 1. Transient expression analysis. Wild-type, mock, and p.Ala225Glu mitochondrial
deficient fibroblasts. Cells were incubated at 37 C for 72 h followed by harvesting. Aft
immunoblot analysis. (A) Acetoacetyl-CoA thiolase enzyme assay. The mean and standa
ions, are shown. (B) Immunoblot analysis. Applied protein amounts are demonstrated (in
CoA:3-oxoacid CoA transferase (SCOT) antibodies. SCOT, succinyl-CoA:3-oxoacid CoA trahave clinical manifestations seen in metabolic encephalopathies,
such as vomiting, convulsions, abnormal tone, and disturbed con-
scious level. Most patients with T2 deficiency recover uneventfully,
as in patient 2 in this paper; however, death or irreversible neuro-
logical damage may ensue, as in patient 1 [1,25,26]. Given the
unspecific clinical presentation, T2 deficiency may be initially mis-
diagnosed by primary care physicians. T2 deficiency may mimic
central nervous system infection, like in the second episode of
patient 1; diabetic ketoacidosis, if associated with stress hyper-
glycemia; or even poisoning, such as of salicylates. Diagnostic clues
towards T2 deficiency include the following: first, a severe ketoaci-
dosis outweighing the associated illness; second, a ratio of free
fatty acids to total ketone body (TKB) (both in mmol/L) less than
0.3 during early fasting stages; and third, a significantly high TKB
relative to blood glucose (TKB  blood glucose > 14; both in
mmol/L) during hypoglycemic states [2,3,27]. Between episodes,
patients with T2 deficiency are usually asymptomatic, except for
potentially irreversible consequences from a prior severe ketoaci-
dotic episode [1]. Intriguingly, some T2-deficient patients, includ-
ing 4 Arabs, have been found to have neurodevelopmental
impairments without identifiable ketoacidotic episodes [6,28].
Metabolic stroke is increasingly recognized in T2 deficiency not
only after acute acidoses, as in mitochondrial respiratory chain
and organic acidurias, but also in the absence of frank metabolic
decompensation [25,26,28]. Direct neurotoxic effects of accumu-
lated isoleucine catabolic intermediates have been proposed
[28,29].
The characteristic abnormalities in blood acylcarnitine (ele-
vated C5:1 and C5-OH), as seen in our patients, and urinary organic
acids (increased 2M3HB, 2MAA, and TIG) profiles, usually provide
supportive evidence for T2 deficiency. However, some patients
whose mutant T2 enzymes retain some residual activities may
show subtle or atypical biochemical abnormalities [21]. Moreover,
another disorder, 2-methyl-3-hydroxybutyryl-CoA dehydrogenase
deficiency, may mimic, in part, the biochemical profile of T2 defi-
ciency [3]. Therefore, a T2 enzyme assay or ACAT1 mutational anal-
ysis is required to confirm the diagnosis. If a novel variant is
discovered, like c.674C > A in patient 2, an expression analysis is
required to prove its pathogenicity. Accordingly, the diagnosis
can be confirmed in the index patient, screening of other family
members for yet asymptomatic patients becomes applicable, and0
Wild-type













acetoacetyl-CoA thiolase (T2) cDNAs were transfected into SV40-transformed T2-
er processing, supernatants from cell extracts were used for an enzyme assay and
rd errors of three independent experiments, before and after addition of potassium
lg) above the lanes. The 1st antibody was a mixture of an anti-T2 and anti-succinyl-
nsferase; T2, mitochondrial acetoacetyl-CoA thiolase.
Table 1
Arab patients with beta-ketothiolase deficiency.a
Population Pt no. Estimated prevalenceb Study type Enzyme assay ACAT1 mutation analysis Ref.
Tunisia 10 – Case reports cYes (1) – [8]
Egypt 8 2.76 NBS pilot study (1) selective screening (7) – – [9,12,13,18]
Syria 5 – Retrospective – – [14]
United Arab Emirates 3 1.4 NBS program (1) retrospective (2) – ec.86_87dupTG, c.854C > T [11,15]
Saudi Arabia 3 – Case report cYes – [6]
Iraq 3 – Selective screening – – [17]
Oman 2 – Selective screening – – [10]
Lebanon 2 1.6 Limited NBS program – – [16]
Libya 2 – Case report – c.674C > A Current study
Yemen 1 – Case report – – [6]
Palestine 1 – Case report dYes – [7]
a This may not be an exhaustive list.
b Per 1  105 newborns.
c Potassium ion-activated acetoacetyl-CoA thiolase assay.
d Coupled assay for detection of defects in isoleucine catabolism distal to enoyl-CoA hydratase, using tiglyl-CoA as a substrate.
e Pathogenicity of these variants have not been confirmed to date. NBS, newborn screening; Pt, patient.
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is also possible. However, it is not necessarily superior to a timely
postnatal diagnosis because T2 deficiency is rarely manifested dur-
ing the neonatal period [1]. Of note, T2 deficiency shows no corre-
lation between genotype and clinical phenotype [1,30].
The management of acute ketoacidotic episodes in T2 deficiency
is aimed at stabilizing the patient’s condition and correcting meta-
bolic derangements. Intravenous glucose is started to suppress
ketogenesis; blood glucose should be maintained at a high-
normal range. Appropriate intravenous fluids and electrolytes are
provided; bicarbonates are only used in severe metabolic acidosis.
Other supportive measures, such as mechanical ventilation, may
also be required. All measures are guided by frequent monitoring
of the patient’s clinical and biochemical conditions [1–3]. Themain-
stay of precautionarymanagement for T2 deficiency includes avoid-
ance of prolonged fasting and early management of infections.
Intravenous glucose should be administeredwhen an associated ill-
ness precludes oral intake. Other non-evidence-based measures,
such as mild protein restriction, avoidance of excessive fat intake,
and carnitine supplementation, are also commonly advised [1,3].
As patient 2 manifested after his younger sister (patient 1) had
already been diagnosed with T2 deficiency, a timely diagnosis,
and both acute and long-term management, were assured. This
likely contributed to the favorable outcome in patient 2.
In conclusion, we report on two siblings with T2 deficiency from
Libya. Both siblings were presented with ketoacidosis, but the
severity and outcomes were quite distinctive. We identified a novel
ACAT1 mutation (c.674C > A) and proved its pathogenicity by tran-
sient expression analysis. The incidence of T2 deficiency may be
high among the Arab population. This disease should be considered
in the differential diagnosis of unexplained ketoacidosis and in
certain clinical circumstances. Patients with T2 deficiency could
have more favorable outcomes with early diagnosis and proper
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